539206
GVBL
Start SIP
Invest Now
Start SIP in GVBL
Performance
- Low
- ₹28
- High
- ₹32
- 52 Week Low
- ₹27
- 52 Week High
- ₹108
- Open Price₹32
- Previous Close₹30
- Volume6,212
Investment Returns
- Over 1 Month -5.78%
- Over 3 Month -24.36%
- Over 6 Month -48.36%
- Over 1 Year -69.69%
Smart Investing Starts Here Start SIP with Genomic Valley Biotech for Steady Growth!
Genomic Valley Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 91.7
- PEG Ratio
- -1.5
- Market Cap Cr
- 9
- P/B Ratio
- 2.3
- Average True Range
- 2.78
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -1.27
- RSI
- 40.6
- MFI
- 68.1
Genomic Valley Biotech Financials
Genomic Valley Biotech Technicals
EMA & SMA
Current Price
₹29.99
+
0.49
(1.66%)
- Bearish Moving Average 15
- Bullish Moving Average 1
- 20 Day
- ₹31.04
- 50 Day
- ₹34.33
- 100 Day
- ₹39.74
- 200 Day
- ₹46.82
Resistance and Support
29.75
- R3 34.78
- R2 33.34
- R1 31.19
- S1 27.60
- S2 26.16
- S3 24.01
Genomic Valley Biotech Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-10-15 | Quarterly Results | |
| 2025-08-07 | Quarterly Results | |
| 2025-05-30 | Audited Results | |
| 2025-02-14 | Quarterly Results | |
| 2024-12-06 | Others | Inter alia - To consider and Approve (1) The Directors Report for the Year 2023-24. (2) 30th AGM of the Company and Other Business Matters. |
Genomic Valley Biotech F&O
About Genomic Valley Biotech
- NSE Symbol
- GVBL
- BSE Symbol
- 539206
- Managing Director
- Mr. Yogesh Agrawal
- ISIN
- INE574D01010
Similar Stocks to Genomic Valley Biotech
Genomic Valley Biotech FAQs
Genomic Valley Biotech share price is ₹29 As on 13 November, 2025 | 22:20
The Market Cap of Genomic Valley Biotech is ₹9.2 Cr As on 13 November, 2025 | 22:20
The P/E ratio of Genomic Valley Biotech is 91.7 As on 13 November, 2025 | 22:20
The PB ratio of Genomic Valley Biotech is 2.3 As on 13 November, 2025 | 22:20
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.